YEW BIO-PHARM GROUP INC

Inactive Instrument

Press Releases Yew Bio-Pharm Group Inc OTC Bulletin Board

Equities

US98584C1018

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

YEW BIO-PHARM GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	29/03/22	AQ
YEW BIO-PHARM GROUP, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	15/11/21	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	16/08/21	AQ
YEW BIO-PHARM GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	27/07/21	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	17/05/21	AQ
YEW BIO P : PHARM GROUP, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/21	AQ
Yew Bio Pharm : Announces New Cosmetic Subsidiary	09/03/21	AQ
YEW BIO-PHARM GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	05/01/21	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	13/11/20	AQ
YEW BIO-PHARM GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	15/09/20	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14/08/20	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	29/06/20	AQ
YEW BIO-PHARM GROUP, INC. : Other Events (form 8-K)	15/05/20	AQ
YEW BIO PHARM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	14/05/20	AQ
YEW BIO-PHARM GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	06/05/20	AQ
YEW BIO-PHARM GROUP, INC. : Other Events (form 8-K)	30/03/20	AQ
Yew Bio Pharm : Reports 2017 Third Quarter Financial Results	13/11/17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer